Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223983 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

StatusActive, Not Recruiting
PhasePhase 1
Started2026-03-26
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Oct 31, 2026 → Feb 2027
See other at-risk trials from Yale University

Amendment history

2026-09-09
Study Status, Study Design, Contacts/Locations v4
Enrollment closed, study ongoing
Final enrollment: 4 participants (planned 10)
Primary completion pushed: 2026-10-31 → 2027-02
Completion pushed: 2026-10-31 → 2027-02
Start date2026-03-06→2026-03-26
Enrollment targetestimated 10→confirmed 4
Study sitesdetails revised at 1 of 1 site
2026-05-07
Study Status, Study Design, Eligibility, Contacts/Locations v3
Recruitment opened
Start dateestimated 2026-03→confirmed 2026-03-06
Eligibility criteriarevised
[...] dures and availability for the duration of the study (up to 96 months: 3-month treatment plus 63-month follow up) Age 18 and older Have a BMI ≥30 (or BMI ≥2 [...] x-en-Y gastric bypass or sleeve gastrectomy within the past threeseven years Meet current DSM-5 criteria for Alcohol Use Disorder [...]
Study sitesdetails revised at 1 of 1 site
2026-02-02
Study Status v2
Start date2025-12→2026-03
2025-11-19
Study Status v1
Start date2025-11-01→2025-12
2025-10-30
Original filing
Yale University
487 trials monitored
See 35 trials at risk
The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
Trial Details
NCT Number NCT07223983
Lead Sponsor Yale University
Conditions Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
Enrollment 4 participants
Start Date 2026-03-26
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-10